re: revised earnings represents 23% drop against a Health related shares are worthwhile buying but not at these prices HSP RHC PRY SHL COH CSL etc forward PEs still well in excess of 20, a hefty premium to the ASX average and to global health stocks. Hopefully HSP downgrade will bring other health share prices down in line with reality.